Stoptions.aiStoptions.aiStoptions.aiStoptions.aiStoptions.ai
Powered by Amora Edge
How it worksResultsPricingMeet StoptieCompareBlog
Sign InStart Free Trial
Stoptions.ai
Powered by Amora Edge

Algorithmic scanning across the S&P 500 & Nasdaq 100. Stock & Options trade cards in your inbox by 9:35 AM ET every trading day.

Product
  • How it works
  • The Algorithm
  • Ticker Setups
  • Pricing
  • Morning Brief
  • Results
  • Compare tools
Account
  • Sign In
  • Start Free Trial
  • Give a gift
  • Dashboard
  • Settings
Company
  • About
  • Contact
  • Support
  • Blog
  • Sitemap
Legal
  • Terms of service
  • Privacy policy
  • Risk disclosure
  • Unsubscribe

© 2026 Stoptions.ai · All Rights Reserved

Not financial advice. Algo-generated setups are not personalised investment advice. Options trading involves significant risk of loss — past performance does not guarantee future results.

Chat with Stoptie
Stoptions.ai›Tickers›MRK
Last updated: Friday, May 22, 2026 · 9:31 AM ET
↻ Next update: Monday, May 25, 2026 · 9:31 AM ET

MRKStock and Options Trade Setup — Merck & Co., Inc.MRK logo

NYSE · Large-Cap Pharmaceuticals · High-liquidity options · Mega cap · ~$210B

▲ Bullish setupHealth CarePharmaceuticalsLow risk↑ Score +4 vs last update
70
Amora Edge Score
70
Top 32% of today's scan
↑ +4 vs last update
Composite of EMA, RSI, RS vs SPY & volume · updated every 72h
69
MRK Win Rate
69%
8 of 12 MRK setups hit target in 2026
Tracks completed Stoptions setups on this ticker since Jan 2026
Why we cover MRK

Merck is built around one of the most valuable pharmaceutical franchises in history — KEYTRUDA's PD-1 checkpoint inhibitor mechanism has now been approved across 40+ cancer indications, making it the broadest-label oncology drug ever developed. Despite KEYTRUDA's U.S. patent cliff in 2028, Merck has constructed a multi-year transition strategy: subcutaneous KEYTRUDA formulation (extending the economic life), co-formulation partnerships (with Moderna for mRNA KEYTRUDA combinations), and a pipeline of next-generation oncology assets including MK-1084 and various ADC programs. The cardiometabolic franchise (sotatercept for pulmonary arterial hypertension) is a multi-billion-dollar opportunity still in its early commercial ramp. Merck trades at a discount to large-cap pharma peers because of KEYTRUDA concentration risk — that discount is an opportunity for investors who believe the pipeline is undervalued.

Score History & Signal Changelog

Preview data

This page is updated every 72 hours with the latest Scan results. Each data point below represents one complete algorithmic snapshot in time.

Score progression across 4 updates
Solid = composite · dashed = components
Signal Changelog
DateUpdateScoreDeltaKey change
May 5#1 Created58—Page created. Defensive pharma setup; KEYTRUDA volumes and sotatercept launch.
May 9#2 Update62+4Sotatercept commercial ramp data positive. Pipeline readout calendar supportive.
May 14#3 Update66+4Volume accelerating. Defensive rotation into large-cap pharma on macro concerns.
May 19#4 Current70+4All signals active. Quality defensive pharma setup confirmed in Strong tier.

Signal Breakdown

EMA Cross
Active
18/25
Above both EMAs; healthcare defensive rotation driving steady uptrend
RSI Zone
Active
17/25
RSI at 61 — momentum zone; pipeline catalyst approach drawing institutional interest
RS vs SPY
Active
18/25
Outperforming SPY +2.2pp; defensive large-cap pharma bid on macro uncertainty
Volume Surge
Active
17/25
1.6× 20-day avg; accumulation ahead of sotatercept commercial ramp data

Today's Trade Card

Setup
MRK $90 CALL
Expires Jul 18, 2026
Premium
$2.20
Target
+64% premium
Stop loss
-41% premium
Breakeven
$92.2
Win prob.
56%
Sizing: Risk ≤ 1% of account
Greeks
Delta
0.40
Theta
-0.06
IVR
22%
IVR class
Low
Loading…

Options Profile

Avg IV (30d)
26%
IVR range (52-wk)
15–44%
Put/call ratio
0.72
Avg daily vol.
28K contracts
Open interest
340K contracts
Next earnings
Jul 29, 2026 (est.)

Risks & Fundamentals

Every setup carries risk. Here's what could move MRK against you, plus the key stats that frame any position.

Beta
0.5
Market cap
~$210B
Risk level
Low risk
Next earnings
Jul 29, 2026 (est.)
Key risks to monitor
  • 1.KEYTRUDA patent cliff in 2028 — biosimilar competition could erode revenues by $10–15B annually as exclusivity expires
  • 2.IRA drug price negotiation — KEYTRUDA was selected for Medicare price negotiation, which will reduce its net pricing from 2028
  • 3.Pipeline execution risk — post-KEYTRUDA growth depends on multiple new products all succeeding, creating binary catalyst risk on key readouts
These are real risks to the long thesis, not a recommendation to short. Stoptions setups are short-dated and stop-protected; size accordingly.

MRK Options Setup — Frequently Asked Questions

Is MRK a good options trade today?+

Merck & Co., Inc. (MRK) currently has an Amora Edge Score of 70/100, ranking it top 32% of today's scan. This composite score is built from four sub-signals — EMA cross, RSI zone, relative strength vs SPY, and volume surge — each scored 0–25. The current read is a bullish setup, so the algorithm is positioned bullish (calls / call debit spreads). A score above 65 typically warrants a trade card with stop and target; below that, the setup is on the watchlist but not actionable.

What is MRK's win rate on Stoptions.ai setups?+

MRK's historical win rate on closed Stoptions setups is 69%. Win rate is calculated as the percentage of past MRK trade cards that hit their target price before stopping out. Win rate is most meaningful once a ticker has 10+ closed trades — individual ticker rates can be noisy at smaller samples. Our portfolio-wide win rate across all closed trades is the more stable benchmark.

What strike and expiry does Stoptions.ai suggest for MRK?+

The strike and expiry are shown on the trade card at the top of this page when the setup is active. Stoptions.ai algorithmically selects strikes targeting delta 0.35–0.45 and expirations 30–45 days out, adjusted for current implied volatility rank (IVR). When IVR is high, the system favors call debit spreads to limit vega risk; when IVR is low, single-leg long calls are preferred. The card includes the contract symbol, mid-price entry, stop, and target.

How often is the MRK setup updated?+

Every 72 hours we refresh MRK's Amora Edge Score and trade card. The underlying scan runs daily at 9:00 AM ET (pre-market) and 9:30 AM ET (post-open), so any new signal change is reflected within one trading session. If MRK drops below the entry threshold or the regime shifts (e.g., SPY enters a confirmed bear), the trade card is replaced with a "no setup" notice automatically.

What does the Amora Edge Score measure for MRK?+

The Amora Edge Score is a 0–100 composite of four technical sub-signals applied to MRK: (1) EMA cross — is the 20-day above the 50-day with both trending up? (2) RSI zone — is momentum in the 50–70 sweet spot, or extended/weak? (3) Relative strength vs SPY — is MRK outperforming the market over 20 sessions? (4) Volume surge — is participation above the 20-day average? Each sub-signal contributes 0–25 points. MRK currently scores 70.

How does MRK compare to other Large-Cap Pharmaceuticals setups?+

MRK's sector rank and percentile against other Large-Cap Pharmaceuticals tickers we track is shown on the /tickers index — sortable by Amora Edge Score, win rate, or sector. For direct comparison, see the "Related Large-Cap Pharmaceuticals Options Setups" panel above. When multiple tickers in the same sector are scoring 80+, the algorithm flags the cluster as a sector rotation signal and may upweight position sizing.

Educational content only — not personalized investment advice. Options carry substantial risk.

The Weekly · Free

Get a Friday Recap Including Setups Like MRK.

Every Friday at 4:30 PM ET — Trade of the Week, Signal Movement, Sector Spotlight, Technical Analysis, and more. A 4-minute read. Free.

No spam. One email Friday afternoon. Unsubscribe in one click.

More from Stoptions.ai
← All tickersBrowse by sectorHow the algorithm worksMorning BriefResultsPricing